Friedenthal Financial Takes Position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Friedenthal Financial bought a new stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 6,915 shares of the specialty pharmaceutical company's stock, valued at approximately $858,000.

Several other hedge funds and other institutional investors have also made changes to their positions in JAZZ. Savant Capital LLC purchased a new stake in shares of Jazz Pharmaceuticals in the fourth quarter valued at about $272,000. New York State Teachers Retirement System lifted its stake in shares of Jazz Pharmaceuticals by 1.2% in the fourth quarter. New York State Teachers Retirement System now owns 43,847 shares of the specialty pharmaceutical company's stock valued at $5,400,000 after purchasing an additional 529 shares during the period. Blue Trust Inc. lifted its stake in shares of Jazz Pharmaceuticals by 73.7% in the fourth quarter. Blue Trust Inc. now owns 1,767 shares of the specialty pharmaceutical company's stock valued at $218,000 after purchasing an additional 750 shares during the period. Rhumbline Advisers lifted its stake in shares of Jazz Pharmaceuticals by 1.1% in the fourth quarter. Rhumbline Advisers now owns 167,560 shares of the specialty pharmaceutical company's stock valued at $20,635,000 after purchasing an additional 1,755 shares during the period. Finally, Sanctuary Advisors LLC lifted its stake in shares of Jazz Pharmaceuticals by 12.2% in the fourth quarter. Sanctuary Advisors LLC now owns 13,193 shares of the specialty pharmaceutical company's stock valued at $1,650,000 after purchasing an additional 1,439 shares during the period. Hedge funds and other institutional investors own 89.14% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. UBS Group upgraded shares of Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and raised their price objective for the company from $145.00 to $179.00 in a research note on Friday, March 7th. Cantor Fitzgerald cut shares of Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and lifted their target price for the stock from $140.00 to $150.00 in a research report on Wednesday, February 26th. Robert W. Baird cut their target price on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. Royal Bank Of Canada cut their target price on shares of Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. Finally, Truist Financial boosted their price objective on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a "buy" rating in a research report on Thursday, March 6th. Two research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $184.00.

Jazz Pharmaceuticals Trading Down 0.7%

Jazz Pharmaceuticals stock traded down $0.73 during trading on Friday, reaching $107.51. The company had a trading volume of 1,053,788 shares, compared to its average volume of 830,550. Jazz Pharmaceuticals PLC has a 12-month low of $95.49 and a 12-month high of $148.06. The stock's 50 day moving average price is $108.14 and its two-hundred day moving average price is $120.08. The firm has a market capitalization of $6.51 billion, a price-to-earnings ratio of 14.33, a PEG ratio of 4.67 and a beta of 0.33. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.97 and a current ratio of 3.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.65 by ($2.97). Jazz Pharmaceuticals had a return on equity of 26.62% and a net margin of 11.86%. The business had revenue of $897.84 million for the quarter, compared to analysts' expectations of $984.16 million. During the same quarter in the prior year, the firm earned $2.68 earnings per share. Jazz Pharmaceuticals's quarterly revenue was down .5% compared to the same quarter last year. As a group, equities analysts expect that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Bruce C. Cozadd sold 1,500 shares of the company's stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $123.75, for a total value of $185,625.00. Following the completion of the transaction, the chief executive officer now directly owns 440,307 shares in the company, valued at approximately $54,487,991.25. This represents a 0.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Seamus Mulligan bought 100,000 shares of the firm's stock in a transaction dated Friday, May 9th. The stock was purchased at an average price of $98.26 per share, with a total value of $9,826,000.00. Following the completion of the purchase, the director now directly owns 100,000 shares of the company's stock, valued at approximately $9,826,000. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 3,000 shares of company stock worth $355,925 over the last ninety days. 4.30% of the stock is owned by company insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.